Phase 4: testing Bisoprolol Oral Tablet for Myocardial Infarct
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
Official registry: https://clinicaltrials.gov/study/NCT06562582 · Vastra Gotaland Region · enrollment listed as 120
What this phase means
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Bisoprolol Oral Tablet, Ramipril Oral Product, or Dapagliflozin Oral Product. The registry lists allocation as randomized. The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
They plan to enroll about 120 people at Gothenburg. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
Interventions: Bisoprolol Oral Tablet, Ramipril Oral Product, Dapagliflozin Oral Product
Primary outcome (registry wording): Measurement of Global longitudinal strain (GLS, %)
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)
Who the registry excludes
- Chronic kidney disease with GFR \< 25 ml/min/1.73 m2
- Pre-existing non-reversible cardiac dysfunction or heart failure
- Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor
- Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician
- Life expectancy less than one year
- Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception
Public study contact (from the registry)
Björn Redfors, Professor
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Sahlgrenska University Hospital — Gothenburg, Sweden (recruiting)
FAQ about this NCT record
Is NCT06562582 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06562582?
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06562582?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary